Phase 1 Placebo-controlled, Randomized Trial of an Adenoviral-vector Based Norovirus Vaccine
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Trial to Determine the
Safety and Immunogenicity of an Adenoviral-Vector Based Norovirus Vaccine (VXA-G1.1-NN)
Expressing GI.1 VP1 and dsRNA Adjuvant Administered Orally to Healthy Volunteers